We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease

News   Apr 07, 2010

 
Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease
 
 
Advertisement
 

RELATED ARTICLES

Blood Test Could Diagnose Baby Brain Damage Just Hours After Birth

News

A newly developed blood test could detect which babies deprived of oxygen at birth are at risk of serious neurodisabilities like cerebral palsy and epilepsy.

READ MORE

RLF-100 Trial Shows Rapid Recovery From Respiratory Failure in Critically Ill Patients With COVID-19

News

A clinical trial of RLF-100 (aviptadil) has shown rapid recovery from respiratory failure in critically ill patients with COVID-19.

READ MORE

Two New Rapid COVID-19 Tests To Be Rolled Out in the UK Ahead of Winter

News

Millions of new rapid coronavirus tests will be rolled out across NHS hospitals, care homes and labs from next week. Both tests will be able to detect COVID-19 and other winter viruses in just 90 minutes and will hugely increase testing capacity ahead of winter.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE